Impact of Platelet Reactivity in ACS Patients on Clinical Outcomes with Triple Antithrombotic Therapy

Impact of Platelet Reactivity in ACS Patients on Clinical Outcomes with Triple Antithrombotic Therapy

Optimal antithrombotic therapy after percutaneous coronary intervention (PCI) in patients on oral anticoagulants (OAC) remains a clinical conundrum. In fact, combining an OAC with dual antiplatelet therapy (triple antithrombotic therapy, TAT) increases the risk of bleeding. Clopidogrel is the only t...

Full description

Bibliographic Details
Main Authors: Julia Gruttemeier, Yves Cottin, Hermann Yao, Emmanuel De Maistre, Maud Maza, Laurent Bonello, Marc Laine, Noemie Resseguier, Marianne Zeller, Laurence Camoin-Jau, Franck Paganelli
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Journal of Clinical Medicine
Subjects:
acute coronary syndrome
triple antithrombotic therapy
VASP index
platelet reactivity
clopidogrel
Online Access:https://www.mdpi.com/2077-0383/10/8/1565

Similar Items

Similar Items